Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Optimal management of constipation associated with irritable bowel syndrome

Authors Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Elisa M, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V

Received 18 December 2014

Accepted for publication 4 March 2015

Published 30 April 2015 Volume 2015:11 Pages 691—703

DOI https://doi.org/10.2147/TCRM.S54298

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Manuele Furnari,1 Nicola de Bortoli,2 Irene Martinucci,2 Giorgia Bodini,1 Matteo Revelli,3 Elisa Marabotto,1 Alessandro Moscatelli,1 Lorenzo Del Nero,1 Edoardo Savarino,4 Edoardo G Giannini,1 Vincenzo Savarino1

1Division of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Division of Gastroenterology, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy; 3Department of Radiology, San Bartolomeo Hospital, Sarzana, Italy; 4Division of Gastroenterology, Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy

Abstract: Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor–patient relationship still seems to be the key for success.

Keywords: IBS, functional gastrointestinal disorders, laxatives

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]